15-LUN-100-HR: A Phase III, Open-label, Randomized Study of Atezolizumab (MPDL3280A, ANTI-PD-L1 Antibody) in Combination With Carboplatin or Cisplatin + Pemetrexed In Patients Who Are Chemotherapy-Naive and Have Stage IV Non-Squamous